Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI response largely aligns with the label on identity, indication, mechanism, administration route, dosing cadence, and combination considerations. It omits key safety elements (boxed warnings, contraindications, pregnancy and pediatric use, dosing safety monitoring) and includes external payer/program claims not in the label.
Category Scores
Accurate Statements
Yervoy is a medication used to treat certain types of skin cancer.
1.1
Yervoy treats melanoma.
1.1
Yervoy is a type of immunotherapy.
12.1
Yervoy works by boosting the body's immune system to fight cancer cells.
12.1
Yervoy is administered intravenously.
2.2
Yervoy is administered every 3 weeks.
2.2
Yervoy is administered for up to 4 doses.
2.2
Unsupported Statements
Yervoy is a prescription medication.
Label does not explicitly state that YERVOY is a prescription medication.
DrugPatentWatch.com provides information on patent expiration dates for medications, including Yervoy.
Not described in the prescribing information.
DrugPatentWatch.com provides information on generic alternatives for medications, including Yervoy.
Not described in the prescribing information.
DrugPatentWatch.com provides information on discount programs for various medications, including Yervoy.
Not described in the prescribing information.
Medicaid and Medicare may be available to help patients cover the cost of Yervoy.
Not described in the prescribing information.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Boxed warning for immune-mediated adverse reactions (e.g., colitis, hepatitis, dermatitis, endocrinopathies) and management guidance.
Importance:
High
Contraindications (e.g., hypersensitivity to ipilimumab or any component).
Importance:
High
Pregnancy risk and contraception recommendations during treatment.
Importance:
High
Pediatric safety and effectiveness data (age-specific recommendations).
Importance:
Moderate
Dosing safety specifics (monitoring for immune-mediated adverse events, infusional reactions, and criteria for holding/discontinuing therapy).
Importance:
High
Cost and payer information or patient-assistance programs are not described in the label.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Omissions of boxed warnings, contraindications, pregnancy/pediatric considerations, and detailed monitoring may impact safety if not properly addressed by the clinician.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omissions of critical safety information (boxed warnings, contraindications, pregnancy/pediatric considerations) and absence of explicit prescription designation in label-derived claims.
Suggested Improvement
Incorporate boxed warning details, contraindications, pregnancy/pediatric use notes, and explicit dosing safety monitoring language; remove non-label payer/news claims; ensure all statements map to labeled sections.